CSIMarket Company Name, Ticker, Suppliers, else..
 
Meridian Bioscience Inc   (VIVO)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 44
 Employees 850
 Revenues (TTM) (Millions $) 302
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 10

Meridian Bioscience Inc
Meridian Bioscience Inc.
is a US-based company that specializes in the development, manufacturing, and distribution of diagnostic test kits, reagents, and related products for the healthcare industry.
The company's main product lines include gastrointestinal, respiratory, and viral and parasitic infection diagnostic test kits, as well as molecular diagnostic tests.
Meridian Bioscience Inc.
was founded in 1976 and is headquartered in Cincinnati, Ohio.
The company's mission is to improve global human health by providing innovative and high-quality diagnostic solutions.
Meridian Bioscience Inc.
is a publicly traded company, listed on the NASDAQ stock exchange under the ticker symbol VIVO.
The company operates through two main segments: Diagnostics and Life Science.
The Diagnostics segment primarily focuses on the development, manufacturing, and distribution of diagnostic test kits for gastrointestinal, respiratory, and viral and parasitic infection diagnostics.
The Life Science segment focuses on providing molecular diagnostic reagents, including RNA and DNA extraction kits and fluorescent dyes for research and clinical applications.
Meridian Bioscience Inc.
serves customers in more than 70 countries worldwide, including hospitals, reference laboratories, research institutes, and physician offices.
The company has established partnerships with leading healthcare organizations and diagnostic companies to expand its product portfolio and to advance healthcare solutions.
In addition, the company has invested heavily in research and development activities to diversify its product offerings and to stay at the forefront of diagnostic innovation.
Overall, Meridian Bioscience Inc.
has developed a reputation as a trusted supplier of quality diagnostic products and as an innovator in the diagnostic industry.


   Company Address: 3471 River Hills Drive Cincinnati 45244 OH
   Company Phone Number: 271-3700   Stock Exchange / Ticker: NASDAQ VIVO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Nymox Pharmaceutical Corporation

NYMX, decline in the corporate behavior throughout the October to December 31 2023 span

The investors did not expect any changes at the top-line throughout the the October to December 31 2023 reporting cycle at the Nymox Pharmaceutical Corporation. Yet, shareholders pay very near attention to the In Vitro and In Vivo Diagnostic Substances company's operating shortfall that came in at $-8.35 million, during the same period.

Volitionrx Limited

A bounce in revenue supported to reduce the shortfall, at the company all along the financial period ending June 30 2024

Energetic Revenue rise in its most recent fiscal period, by 82.977 % to $0.40 million supported to cut losses to $-0.08 per share, from $-0.14 in similar financial reporting period a year prior. Volitionrx Limiteds' top-line went up faster in contrast to the the revenue at virtually all of the In Vitro and In Vivo Diagnostic Substances industry contemporaries, in the second quarter of 2024 the majority entities in In Vitro and In Vivo Diagnostic Substances industries experienced an average top-line rise of 6.33% relative to the similar period a year ago.

Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc: Revenue Soars, But Profitability Remains Elusive Amid April-June 2024 Surge

company announced very robust Revenue advance year on year to $0.01 million in the second quarter of 2024, but increased a loss per share at $-0.06. Cardio Diagnostics Holdings Inc s' revenue rose at higher rate in contrast to the the top-line at almost all of the In Vitro and In Vivo Diagnostic Substances industry contemporaries, in the second quarter of 2024 the majority entities in In Vitro and In Vivo Diagnostic Substances industries reported the revenue advance of 6.22% relative to the corresponding period a year ago.

Celldex Therapeutics Inc

An extraordinary conduct by Celldex Therapeutics Inc over the second quarter of 2024 earnings season

For the second quarter of 2024 earnings season Celldex Therapeutics Inc decreased a loss per share of $-0.54 per share compare to $-0.65 a year prior and EPS improved from $-0.56 per share from the previous quarter. The revenue advanced sharply by 832.09 % to $2.50 million from $0.27 million in the similar quarter a year prior and sequentially Revenue doubled by 1501.282 % from $0.16 million. In Vitro and In Vivo Diagnostic Substances company's revenue, surge in the second quarter of 2024 correlates favorably to its In Vitro and In Vivo Diagnostic Substances industry peers, which experienced all in all 6.22 % top-line advance in the same period thus far.

Idexx Laboratories Inc

IDEXX Laboratories: Revenue Rises, But Earnings Take a Dive in Q2 2024

IDXX reported contradictory results in the April to June 30 2024 time-frame, where Revenue grew by 6.309 % to $1.00 billion compared to $943.63 million on a year-over-year basis, while earnings decreased by -8.61 % to $2.44 per share, as a comparison to $2.67 in the prior year reporting period. Idexx Laboratories Incs' top-line, growth in the second quarter of 2024 compares favorably to its In Vitro and In Vivo Diagnostic Substances sector contemporaries, which had all in all 4.46 % revenue elevation during the matching time so far.







Meridian Bioscience Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com